Coder-rony commited on
Commit
8c06239
·
verified ·
1 Parent(s): cbc6cc8

raw shard 364

Browse files
Files changed (1) hide show
  1. raw/shard_00364.jsonl +1 -0
raw/shard_00364.jsonl ADDED
@@ -0,0 +1 @@
 
 
1
+ {"session_id": "atlas-67ea75b3af", "tier": "text", "task_instruction": "Determine the current status of gemtuzumab ozogamicin's availability in the United States for treating relapsed AML in patients over 60 years old who are not candidates for high-dose chemotherapy.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "Gemtuzumab ozogamicin, also known as Mylotarg, was approved in the United States in 2000 for treating relapsed AML in individuals over 60 who are not eligible for high-dose chemotherapy.", "image_path": null, "audio_path": null}, "reasoning": "This indicates that the drug was available for this specific patient population at the time of approval.", "action": {"type": "text_response", "value": "Note the approval status and target demographic."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "The drug was voluntarily withdrawn from the market by its manufacturer, Pfizer, in 2010.", "image_path": null, "audio_path": null}, "reasoning": "This suggests that despite its approval, the drug was no longer available after 2010.", "action": {"type": "text_response", "value": "Identify the reason for withdrawal and its implications on availability."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "Hematopoietic stem cell transplant remains the only proven potentially curative therapy for relapsed AML, especially for those who haven't undergone such a transplant yet.", "image_path": null, "audio_path": null}, "reasoning": "This highlights that while Mylotarg was an option, it is no longer available, and other treatments might be considered now.", "action": {"type": "text_response", "value": "Consider alternative treatments available post-withdrawal."}, "refers_back_to": null}, {"step_index": 3, "observation": {"text": "The passage does not mention any subsequent approval or reintroduction of gemtuzumab ozogamicin after 2010.", "image_path": null, "audio_path": null}, "reasoning": "This implies that as of the latest information provided, the drug remains unavailable in the United States for the specified use.", "action": {"type": "text_response", "value": "Conclude on the current status based on available information."}, "refers_back_to": null}], "task_complexity": "high", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "For people with relapsed AML , the only proven potentially curative therapy is a hematopoietic stem cell transplant , if one has not already been performed . In 2000 , the monoclonal antibody @-@ linked cytotoxic agent gemtuzumab ozogamicin ( Mylotarg ) was approved in the United States for people aged more than 60 years with relapsed AML who are not candidates for high @-@ dose chemotherapy . This drug was voluntarily withdrawn from the market by its manufacturer , Pfizer in 2010 ."}